Russian Private Equity Fund announced the closing of a deal with the pharmaceutical company R-Pharm Alexey Repyk. The share of the company bought by the joint Russian-Japanese equity fund is estimated at 10%, the deal value is not disclosed.
"Today we have finalized and announced the closing of the deal with R-Farm, the investment in the pharmaceutical industry," said the head of RPEF Kirill Dmitriev right before the Eastern Economic Forum (VEF) in Vladivostok on September 10.
In December 2017, RPEF and the Japanese bank JBIC announced the opening of a Russian-Japanese equity fund with an investment of $ 1 billion to co-finance joint projects between the two countries. It was expected that the first project in which the fund would take part would be the purchase of a share of the Russian pharmaceutical company R-Farm. The volume of investments in the project was not disclosed, but Dmitriev mentioned that RPEF was going to invest in the transaction "tens of millions dollars."
In April 2017, another Japanese company, Mitsui, acquired 10% of R-Farm shares, the press service of the company said. The deal value was not officially disclosed. According to various sources, it ranged from $ 170 million to $ 200 million.
JSC R-Pharm is a Russian pharmaceutical company. The key areas of activity are the production of drugs and biologicals, research and development of new drugs and technologies, and the supply of pharmaceutical products to foreign producers on the Russian market.
According to the results of 2016, R-Pharm was the leader of the Vademecum rating "TOP 100 operators of the drug state order" with revenues of more than 55 billion rubles from state deliveries alone.
© All rights reserved, 2015-2019